HS 20105
Alternative Names: HS-20105Latest Information Update: 21 Dec 2023
At a glance
- Originator Hansoh BioMedical R&D Company
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 27 Nov 2023 Preclinical trials in Solid tumours in China (IV)
- 22 Nov 2023 Hansoh Biomedical R&D company plans a phase I/II trial for Solid tumors (Second-line therapy, Late-stage disease) (IV) in March 2024 (NCT06144723)
- 25 Sep 2023 National Medical Products Administration approves IND application for HS 20105 in Solid tumors in China